The role of prothrombotic mutations in patients with Buerger's disease

Avcu F., Akar E., Demirkilic U., YILMAZ E., Akar N., Yalcin A.

THROMBOSIS RESEARCH, cilt.100, sa.3, ss.143-147, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 100 Sayı: 3
  • Basım Tarihi: 2000
  • Doi Numarası: 10.1016/s0049-3848(00)00310-8
  • Dergi Adı: THROMBOSIS RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.143-147
  • Anahtar Kelimeler: Buerger's disease, factor V Leiden, prothrombin 20210 G -> A, factor V 4070 A -> G, ACTIVATED PROTEIN-C, FACTOR-V-LEIDEN, TURKISH POPULATION, VENOUS THROMBOSIS, GENE, RESISTANCE, PLASMA, RISK
  • Ankara Üniversitesi Adresli: Hayır

Özet

Thromboangiitis obliterans (TAO), or Buerger's disease, is a segmental occlusive inflammatory disorder of the arteries and veins, and etiopathogenesis is still obscure. In the present study we investigated the prevalence of prothrombin 20210 G-->A, factor V 1691 G-->A (Factor V Leiden), and factor V 4070 A-->G (His 1299 Arg) mutations, found to be associated with increased risk for vascular thrombosis, in 36 patients with TAO. We performed a case-control study of these mutations. The odds ratio for prothrombin 20210 A allele compared with G allele was 7.98 (95% confidence intervals 2.45-25.93). Only this prothrombotic genetic factor was associated with the risk of TAO (p=0.032). In conclusion, carrying the prothrombin 20210 G-->A may be an important prothrombotic risk factor of TAO. This genetic predisposition must be screened in these patients routinely, and clinical importance must be supported by further investigations. (C) 2000 Elsevier Science Ltd. All rights reserved.